Is a
Patent attributes
Patent Jurisdiction
Patent Number
Date of Patent
August 16, 2011
Patent Application Number
10521109
Date Filed
July 10, 2003
Patent Citations Received
Patent Primary Examiner
Patent abstract
The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
